Quantification of metastatic prostate cancer whole-body tumor burden with 18F-FDG PET parameters and associations with overall survival after first-line abiraterone …

AG Wibmer, MJ Morris, M Gonen, J Zheng… - Journal of Nuclear …, 2021 - Soc Nuclear Med
New biomarkers for metastatic prostate cancer are needed. The aim of this study was to
evaluate the prognostic value of 18F-FDG PET whole-body tumor burden parameters in …

[HTML][HTML] Role of baseline and post-therapy 18F-FDG PET in the prognostic stratification of metastatic castration-resistant prostate cancer (mCRPC) patients treated …

M Bauckneht, S Capitanio, MI Donegani, E Zanardi… - Cancers, 2019 - mdpi.com
Radium-223 dichloride (Ra223) represents the unique bone-directed treatment option that
shows an improvement in overall survival (OS) in metastatic castrate resistant prostate …

Prognosis related to metastatic burden measured by 18F-fluorocholine PET/CT in castration-resistant prostate cancer

SA Kwee, J Lim, A Watanabe… - Journal of Nuclear …, 2014 - Soc Nuclear Med
This study investigated the prognostic significance of metabolically active tumor volume
(MATV) measurements applied to 18F-fluorocholine PET/CT in castration-resistant prostate …

Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer

H Jadvar, B Desai, L Ji, PS Conti, TB Dorff… - Journal of Nuclear …, 2013 - Soc Nuclear Med
The aim of this prospective investigation was to assess the association of parameters
derived from baseline 18F-FDG PET/CT with overall survival (OS) in men with castrate …

[HTML][HTML] The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer …

M Bauckneht, F Bertagna, MI Donegani… - Prostate Cancer and …, 2021 - nature.com
Background We aimed to test whether the prognostic value of 18 F‐Fluorodeoxyglucose
Positron Emission Tomography/Computed Tomography (FDG-PET/CT) in metastatic …

Prognostic value of 18F–choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide

P Caroli, U De Giorgi, E Scarpi, L Fantini… - European Journal of …, 2018 - Springer
Purpose The role of 18F–choline positron emission tomography/computed tomography
(FCH-PET/CT) in patients with metastatic castration-resistant prostate cancer (mCRPC) has …

[HTML][HTML] The prognostic role of baseline metabolic tumor burden and systemic inflammation biomarkers in metastatic castration-resistant prostate cancer patients …

M Bauckneht, SE Rebuzzi, A Signori, MI Donegani… - Cancers, 2020 - mdpi.com
Simple Summary Radium-223 is an alpha-emitting radioisotope that selectively binds to
increased bone turnover areas, such as metastatic sites, acting as a bone-seeking calcium …

Prediction of PSA progression in castration-resistant prostate cancer based on treatment-associated change in tumor burden quantified by 18F-fluorocholine PET/CT

J Lee, MM Sato, MN Coel, KH Lee… - Journal of Nuclear …, 2016 - Soc Nuclear Med
Measurements of metabolically active tumor volume (MATV) can be applied to 18F-
fluorocholine PET/CT to quantify whole-body tumor burden. This study evaluated the serial …

Role of volumetric parameters obtained from 68 Ga-PSMA PET/CT and 18F-FDG PET/CT in predicting overall survival in patients with mCRPC receiving taxane …

Y Güzel, H Kömek, C Can, İ Kaplan, N Akdeniz… - Annals of Nuclear …, 2023 - Springer
Objective The aim of this study was to determine the prognostic role of volumetric
parameters and Pro-PET scores obtained from 68 Ga-prostate-specific membrane antigen …

Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers

F Maines, O Caffo, D Donner, I Sperduti, E Bria… - Future …, 2016 - Future Medicine
Aim: High rate of non-target lesions in metastatic castration-resistant prostate cancer usually
limits applicability of Response Evaluation Criteria in Solid Tumors (RECIST) criteria, and …